We are a life science innovation center that supports health tech entrepreneurs providing strategic mentorship and resources, experts and office space for growth.



THE MISSION

To accompany health tech startups to their next significant valuation milestones.

OFFERS

Neighborhood offers tailed in-residence mentoring, coaching and global access to health tech entrepreneurs.

Last events

meetings

Which human resource strategy for start-ups’ scale-up?

Wednesday July 3, 2019 - 18 h 00 min-21 h 00 min

Attract talent, choose the right profiles, ensure team cohesion, grow human capital: the HR strategy...

View more

meetings

Roundup of J.P. Morgan’s Annual Healthcare Conference

Tuesday January 15, 2019 - 18 h 00 min-21 h 30 min

View more

meetings

Healthtech : Digital IP and Open Source

Thursday November 8, 2018 - 18 h 00 min-20 h 00 min

View more

COMMUNITY

HOW TO APPLY

Tell us about your idea, technology, or innovation and how we can work together to empower you to reach your next milestone in product development.

Join us I have a question

Would like to learn more
on our programs or take a tour?

KNOW MORE

THERAPEUTIC AREA
Cardiology, neurology, stroke
LOCATION COUNTRY
Paris, France

WEBSITE
https://www.op2lysis.com

OP2lysis

Op2Lysis develops the first treatment for hemorrhagic stroke a life-threatening disease that affects >1,5M people every year worldwide. Op2lysis program aims at validating the clinical safety and the efficacy of its therapeutic solution to be ready to enter advanced phases of development by 2022. Op2Lysis is a biotech company dedicated to the development of innovative products to improve the benefit of lytic treatment in stroke, the first cause of acquired handicap worldwide. Christophe GAUDIN and Jérôme PARCQ are the co-founders of Op2Lysis, which benefits from their complementary experiences and skills.

THERAPEUTIC AREA
Cardiology, neurology, stroke
LOCATION COUNTRY
Paris, France

WEBSITE
https://www.op2lysis.com

OP2lysis

Op2Lysis develops the first treatment for hemorrhagic stroke a life-threatening disease that affects >1,5M people every year worldwide. Op2lysis program aims at validating the clinical safety and the efficacy of its therapeutic solution to be ready to enter advanced phases of development by 2022. Op2Lysis is a biotech company dedicated to the development of innovative products to improve the benefit of lytic treatment in stroke, the first cause of acquired handicap worldwide. Christophe GAUDIN and Jérôme PARCQ are the co-founders of Op2Lysis, which benefits from their complementary experiences and skills.

THERAPEUTIC AREA
Pharmacodynamic Modeling and Artificial Intelligence

LOCATION COUNTRY
Paris, France

Hillo

Hillo develops the first AI-based decision support platform for diabetic patients, based on a blood glucose levels predictive system that adapts to every patient’s physiology and habits. Our technology combines pharmacodynamic modeling and artificial intelligence, we develop tools for patients to help them anticipate and avoid hypo- or hyperglycemia, and for care teams to help them understand each patient’s specific glycemic response. We’ve demonstrated outstanding results and accuracy of our predictive technology through trials in hospitals.

THERAPEUTIC AREA
Neuropathies
LOCATION COUNTRY
Paris, France

Neurophoenix

Neurophoenix is a biotechnology company developing a revolutionary treatment for chronic and acute optic neuropathies such as glaucoma or retina ischemia. This novel approach is based on a molecule derived from a virus that has the remarkable property of reactivating the survival mechanism of injured neurons. Our molecule is the result of many years of academic research carried out by Monique Lafon, director of the Viral Neuro-immunology laboratory at Institut Pasteur. This research identified a molecule produced by the rabies virus with the remarkable capacity to both keep neurons alive (neuroprotection) and also stimulate axon regrowth from damaged neurons (neuroregeneration).

THERAPEUTIC AREA
Neuropathies
LOCATION COUNTRY
Paris, France

Aivision

Neurophoenix is a biotechnology company developing a revolutionary treatment for chronic and acute optic neuropathies such as glaucoma or retina ischemia. This novel approach is based on a molecule derived from a virus that has the remarkable property of reactivating the survival mechanism of injured neurons. Our molecule is the result of many years of academic research carried out by Monique Lafon, director of the Viral Neuro-immunology laboratory at Institut Pasteur. This research identified a molecule produced by the rabies virus with the remarkable capacity to both keep neurons alive (neuroprotection) and also stimulate axon regrowth from damaged neurons (neuroregeneration).

THERAPEUTIC AREA
Neurodegenerative and (auto)-immune diseases
LOCATION COUNTRY
Paris, France

Encefa

Encefa is a preclinical biotechnological company stemming from the French “Brain and Spine Institute” (Pitié Salpêtrière Hospital, Paris).

Encefa develops monoclonal antibodies (mAbs) against neurodegenerative and (auto)-immune diseases, to be disease modifier. They will go against Amyotrophic Lateral Sclerosis (ALS) for their First in Man.

Encefa mAbs trigger an unprecedented mechanism of action that simultaneously activates cells’ autophagy and metabolism (on neurons), while regulating inflammation (on immune cells).
Today, Encefa has its Lead, an optimized humanized mAb with its efficacy validated in 3 different mice models and showing a low toxicity profile, ready to enter its preclinical development phase.

THERAPEUTIC AREA
Cell Therapies

LOCATION COUNTRY
Paris, France

WEBSITE
https://treefrog.fr/

TreeFrog

TreeFrog Therapeutics is a stem cell company that will enable millions of patients to access the medical revolution of cell therapies by overcoming current critical manufacturing issues.

Founded in 2018 in Bordeaux and “Grand Prix” of the French i-Lab contest for deep tech innovation, TreeFrog Therapeutics has developed C-Stem™: a proprietary technology for the mass-production of stem cells, that dramatically reduces treatment costs while introducing a new quality standard for cell therapies.

Following a series A round of 7.1M€ in May 2019, TreeFrog Therapeutics is establishing strategic partnerships and co-developments with cell therapy players worldwide to help them secure cell production and quality, fasten clinical development, and facilitate market access.

THERAPEUTIC AREA
Industrie pharmaceutique

LOCATION COUNTRY
Pessac, France

OP2 Drugs

OP2 Drugs SAS (“OP2″) is a biotech company that aims at developing innovative life-saving drugs for unmet medical needs, especially in the cardiology field. Our first patented compound, OP2113, which targets mitochondrial dysfunction, is in preclinical stage, with a strong scientific rational.

Based on strategic partnerships in Europe and in the US, we are generatling growth and value for all stakeholders thanks to our drug candidates pipeline, in several indications. OP2 is planned to move forward to clinic in 2018.

Located in Pessac, close to Bordeaux (France), OP2 Drugs is supported by Unitec (Bordeaux), managed by Frédéric Marin (CEO) and Nicolas Pineau (COO), and funded by ambitious financial players.